Helius Medical Technologies announced the addition the Montefiore Medical Center to its PoNS Therapeutic Experience Program. Montefiore joins five other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator therapy in patients with multiple sclerosis. Montefiore’s participation in the study will be held at the Burke Rehabilitation Center and led by Dr. Christopher Langston, medical director of The Madlyn Borelli Multiple Sclerosis Center at Montefiore Nyack Hospital.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HSDT:
- Is HSDT a Buy, Before Earnings?
- Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
- Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023
- Helius Medical expands stroke trial at MUSC
- Helius Medical Technologies, Inc. Expands Stroke Trial at the Medical University of South Carolina
